Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

(2:57)

Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer

(2:21)

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed \u0026 pembrolizumab

(1:19)

Phase II Study of Maintenance Pembrolizumab in Extensive Stage Small Cell Lung Cancer

(2:58)

EA5163/S1709/INSIGNA: the timing of pembrolizumab +/- chemo as 1L treatment and maintenance in NSCLC

(2:21)

Maintenance therapy for bladder cancer

(1:11)

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

(1:48)

Maintenance therapy in urothelial carcinoma

(1:2)

The Potential for IO Use as Maintenance Therapy in NSCLC

(5:51)

ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study

(3:21)

Maintenance Therapies for Patients with Non-Small Cell Lung Cancer

(1:40)

Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?

(4:34)

How pembrolizumab will change the management of advanced lung cancer

(57)

Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy Use

(3:2)

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed \u0026 pembrolizimab

(2:26)

Switch Maintenance Strategy for Metastatic Bladder Cancer

(4:20)

Advanced-Stage Nondriver NSCLC: Maintenance Therapy

(3:25)

David R. Gandara, MD, on continuing pemextrexed maintenance

(25)

Phase II Trial Considers the Benefit of Switch Maintenance in Urothelial Cancer

(1:34)

Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies

(55:13)